ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
-0.06 (-0.65%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Company Description

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.

The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis.

It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 24
CEO Richard Lowenthal M.B.A., M.S., MSMSEL

Contact Details

11682 El Camino Real, Suite 120
San Diego, California 92130
United States
Phone 858-771-9307

Stock Details

Ticker Symbol SPRY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001671858
ISIN Number US82835W1080
Employer ID 81-1489190
SIC Code 2834

Key Executives

Name Position
Richard Lowenthal M.B.A., M.S., MSMSEL Founder, President, Chief Executive Officer and Director
Dr. Sarina Tanimoto M.B.A., M.D. Co-Founder and Chief Medical Officer
Eric Karas Chief Commercial Officer
Dr. Robert Bell Ph.D. Co-Founder and Chief Science Officer
Kathleen D. Scott CPA Chief Financial Officer
Brian T. Dorsey M.S. Chief Operations Officer
Alexander A. Fitzpatrick Esq. Chief Legal Officer and Secretary
Daniel Relovsky Senior Vice President of Marketing
Harris Kaplan M.B.A. Executive Vice President of Commercial Strategy
Justin Chakma Chief Business Officer and Secretary

Latest SEC Filings

Date Type Title
Mar 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 21, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Mar 7, 2024 8-K Current Report
Feb 26, 2024 144 Filing
Feb 26, 2024 144 Filing
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 9, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report